On November 3, 2022 Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), reported that the company will present three posters related to the company’s lead drug candidate, ELA026, at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting being held in New Orleans, Louisiana, December 10-13, 2022 (Press release, Electra Therapeutics, NOV 3, 2022, View Source [SID1234622912]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With ELA026, Electra is taking a first-in-class approach to targeting SIRP to enable precise depletion of pathological immune cells. ELA026 is currently in Phase 1 clinical studies, including a Phase 1b trial in patients with secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disease.
Details of the poster presentations are as follows:
Title: Characterization of ELA026, a clinical-stage monoclonal antibody that rapidly and potently depletes myeloid cells and T lymphocytes
Presenter: Sandip Panicker, PhD, Chief Scientific Officer, Electra Therapeutics
Session Date and Time: Monday, December 12, 2022, 6:00 PM – 8:00 PM
Location: Ernest N. Morial Convention Center, Hall D
Abstract Number: 3722
Title: Trial in progress: A phase 1b study of ELA026 in patients with secondary hemophagocytic lymphohistiocytosis (sHLH)
Presenter: Gary Patou, MD, Chief Medical Officer, Electra Therapeutics
Session Date and Time: Monday, December 12, 2022, 6:00 PM – 8:00 PM
Location: Ernest N. Morial Convention Center, Hall D
Abstract Number: 3730
Title: Identification and characterization of a retrospective cohort of secondary hemophagocytic lymphohistiocytosis (sHLH) patients in the US
Presenter: Catherine Broome, MD, Medstar Georgetown University Hospital
Session Date and Time: Sunday, December 11, 2022, 6:00 PM – 8:00 PM
Location: Ernest N. Morial Convention Center, Hall D
Abstract Number: 2415
About Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory condition for which there is no approved treatment. sHLH can be triggered by cancer, immunotherapy, infection, or an autoimmune disease. Once triggered, sHLH requires immediate intervention. Without treatment, it can rapidly progress from symptoms such as persistent fever, hepatomegaly and/or splenomegaly, and cytopenias, to multi-organ failure and death. Even with the current use of off-label treatments that have toxicity challenges and limited efficacy, sHLH remains fatal in approximately 60% of adults within 3.5 years.